Fresenius gains development options on up to 37 WuXi Biologics biosimilar candidates
Company / institutional announcement · Fresenius
Source published: · Event / reporting date: 2026-11-02
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What changed
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Why it may matter
Analysis: The agreement may generate sustained development and comparability work, but actual project selection, manufacturing allocation, and approvals remain uncertain.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections